Vážený uživateli, je nám líto, ale Váš prohlížeč nepodporuje plné zobrazení webu. Doporučujeme Vám přejít na jeho aktuálnější verzi (MS Edge) nebo na některý z nejčastějších prohlížečů (Chrome, Firefox, Safari).

Amunix signs takeover pact with Sanofi worth $1 billion targeting immune-oncology platforms

SOTIO Biotech

17/1/2022 | 3 minuty čtení

Vytisknout
Kopírovat odkaz

Sanofi announced that it has entered into an agreement to acquire Amunix Pharmaceuticals, an immuno-oncology company leveraging its proprietary, clinically validated XTEN and innovative universal protease-releasable masking technology platform, Pro-XTENT, to discover and develop transformative T-cell engagers (TCE) and cytokine therapies for patients with cancer.

Amunix’s pipeline, which includes lead candidate, AMX-818, a masked HER2-directed TCE, offers a strong strategic fit with Sanofi’s focus on developing potentially transformative cancer therapies in immuno-oncology.

PARTNERING

Sanofi will acquire Amunix for an upfront payment of approximately $1 billion and up to $225 million upon achievement of certain future development milestones. Amunix’s proprietary XTEN masks and cleavable linkers are a next-generation protein engineering approach that allows biologics to circulate in “stealth” mode, becoming active preferentially in disease specific micro-environments.

Amunix’s technology offers the potential to overcome challenges that have plagued the adoption of T-Cell Engagerbispecific antibodies for solid tumors, including unwanted immune attack of normal healthy cells and systematic immune system activation leading to side effects as cytokine release syndrome.

Immatics and BMS enter into global license for TCR bispecific program IMA401

Immaticsand BMS announced they have entered into a license, development and commercialization agreement for Immatics’ TCR Bispecific candidate, IMA401. Immatics will receive an upfront payment of $150 million as well as up to $770 million in development, regulatory and commercial milestone payments, in addition to tiered double-digit royalty payments on net sales of IMA401. Immatics retains the options to co-fund US development in exchange for enhanced US royalty payments and/or to co-promote IMA401 in the US.

IMA401 is the most advanced product candidate in Immatics’ TCR Bispecifics pipeline, called TCER (T Cell Engaging Receptors), in which one binding region targets MAGEA4/8, a highly prevalent antigen in multiple solid tumors, and the other region engages and activates T cells. In preclinical proof-of-concept studies, IMA401 has shown anti-tumor activity with complete remissions in various in vivo tumor models including patient-derived xenograft models.

The agreement outlines a development plan under which both companies will collaborate to advance the program through clinical development.

Novartis forges closed links with Beigene taking $1 billion option on TIGIT cancer drugs

Novartis has forged even stronger links with Beigene, taking an option on the latter’s late-stage TIGIT inhibitor cancer immunotherapy, ociperlimab, in a deal worth up to $1 billion. Novartis will pay Beigene $300 million upfront in the option, collaboration and license agreement plus up to $700 million if it exercises its option before late 2023. BeiGene would be eligible for another $1.9 billion in milestones, plus royalties.

Ociperlimab is being studied in Phase 3 for advanced NSCLC, and Novartis said it could be combined with the PD-1 inhibitor tislelizumab that Novartis has already bought rights to in North America, Europe and Japan in a $2.2 billion deal with Beigene.

Biosion licenses out anti-Trop2 humanized MAb to Obi Pharma

Obi Pharma acquired global rights to BSI-04702, an TROP2 humanized monoclonal antibody from Biosion. Obi is granted exclusive rights for further preclinical and clinical development, registration and commercialization of the candidate as ADC and other derivative products. Obi Pharma will pay licensing fees to Biosion, including upfront payment, future development milestones and net sales royalties. Specific terms were not disclosed.

BSI-04702 was created through Biosion's Syntracer HT-endocytosis platform, a high-throughput endocytosis screening application that can identify antibody candidates with high internalization rates. TROP2 is a protein located on the surface of cells.

Legochem licenses out its ADC compound to Iksuda in a $1 billion deal

Legochem Biosciences has licensed out its ADC LCB-14 to IksudaTherapeuticsin the duo’s latest deal that is worth $1 billion. Legochem will receive $50 million in an upfront payment and near-term milestones, and up to $950 million in developments, regulatory and commercial milestones. If Iksuda initiates a technology transfer to a third party during the drug’s development, Legochem will be entitled to a pre-determined portion of the upfront payment and all milestones.

LCB-14 is designed to treat HER2 cancers including breast, gastric, ovarian and urothelial cancers. It was developed using Legochem’sConjuall platform, which connects antibodies, linkers and efficient toxin release technologies to create ADCs. Legochem out-licensed LCB-14’s greater China rights to Fosun in 2015.

Overview of transactions in oncology (values in m$)

Source

Partner

Product

Stage

Rights

Value

UF

MS

EUSA Pharma

Recordati

Acquisition of company with anti-GD2 mabQarziba against neuroblastoma and three other marketed compounds

Market

NV

846

846

0

Karyopharm Therapeutics

Menarini Group

Commercial rights to marketed drug Nexpovio/Xpovio approved to treat multiple myeloma

Market

EU

278

75

203

Beigene

Novartis

Licensing option to anti-TIGIT targeting antibody ociperlimab developed against NSCLC

Ph 3

WW

2 900

300

2 600

ITM Isotope Technologies

Grand Pharma Group

License to 177Lu-edotreotide ITM-11 against gastroenteropancreatic-neuroendocrine tumors

Ph 3

CN

589

NA

NA

Nanjing Lead Biolabs

Beigene

License to anti-LAG3 antibody LBL-007 developed against cancer

Ph 1/2

Ex-CN

772

30

742

Legochem Biosciences

Iksuda Therapeutics

License to LCB-14 ADC designed to treat HER2 cancers

Ph 1

Ex-KR,       CN

1 000

50

950

Foghorn Therapeutics

Eli Lilly

License to up to five selective BRM inhibitors for BRG1 mutated cancers

Precl

Ex-US

1 680

380

1 300

Amunix Pharma

Sanofi

Acquisition of company developing five T cell engagers and cytokines against cancer

Precl

NV

1 000

1 000

0

Immatics

BMS

License to TCR bispecific IMA401 targeting MAGE4/8 against solid tumors

Precl

WW

920

150

770

Molecular Partners

Novartis

License to DARPin-conjugated radioligand therapies targeting specific tumor associated antigens

Res

WW

580

20

560

NASDAQ Initial Public Offerings (IPOs) in oncology

Company

Ticker

Lead product

Technology

Stage

Amount m$

Price $

Genenta Sciences SpA

GNTA

Temferon

HIV-derived lentivirus delivered gene therapy against glioblastoma

Phase 1/2

36.0

11.5

Immix Biopharma

IMMX

iMX-110

doxorubicin + curcumin against soft tissuesarcoma

Phase 1/2

21.0

5

Sdílet na sociálních sítích

Sdílet na sociálních sítích

Vytisknout

Kopírovat odkaz